2025-02-14 IDOPRESS
SEOUL,South Korea,Feb. 13,2025 -- DAAN Biotherapeutics,a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies,has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).
By leveraging DAAN Biotherapeutics' next-generation antibody technology,built upon its exceptional target discovery and antibody development capabilities,LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients.
DAAN Biotherapeutics has successfully established a proprietary pipeline for efficiently developing antibodies targeting overexpressed tumor targets in solid cancers through a strategic partnership with OmniAb.
Byoung Chul Cho,MD,the CEO of DAAN Biotherapeutics,stated,"We will continue to develop state-of-the-art antibodies targeting solid tumors and collaborate with global pharmaceutical companies in the ADC field. Beyond ADCs,we also aim to become a global leader in solid tumor-targeting T-cell engagers using our proprietary TACTIC (Tumor Targeting Conditionally Activated T Cell Engager) platform."
World’s First Digital Product Passport Universal Framework Launched Forging a New Digital Mutual Trust Foundation for Global Sustainable Development
GMSWAP on Binance Live: Reinventing Cross-Chain Liquidity and Launching Strategic Airdrop Campaign
LOOP Finance: A Financial Institutional Experiment in the Web3 Republic
truth revealed about why farmers sprayed manure on 'illegal campers'
danish zoo asks owners to donate unwanted animals to feed to predators
Atrend Ltd Partners with Members to Officially Enter the U.S. Pre-Market Trading Session, Ushering in a New Era of AI-Driven Investing
©copyright2009-2020Fresh life